Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CRB Bio II and ADE Capital Sodical Commits €3M Seed Investment Round

Published: Monday, July 08, 2013
Last Updated: Monday, July 08, 2013
Bookmark and Share
Raman Health Technologies develops a new non invasive diagnostic technology platform for multiple diseases based on Raman laser spectroscopy.

CRB Bio II and ADE Capital Sodical have committed a €3M seed investment round in Raman Health Technologies, a new start up company developing a new non invasive diagnostic technology platform based on Raman laser and Infrared spectroscopy. Its first indication will be for the early diagnosis of Alzheimer disease in a blood sample.

Raman Health, based at the Boecillo Technology Park, is a spin-off of the University of Valladolid Fernando Rull, Professor of Crystallography and Mineralogy of the University of Valladolid is one of the key persons in this project.

This financing round will allow the company to achieve its strategic objectives, namely the establishment of a new expanded lab facility to foster the development of the methodology for the detection of spectroscopic biomarkers and the development of a robust diagnostic platform.

Laser to detect Alzheimer
The platform being developed by Raman Health Technologies will be used for the diagnosis of different diseases in a blood sample.

In the case of Alzheimer disease, it avoids the need of invasive techniques, like the lumbar punction to obtain cerebrospinal fluid and will provide a significant improvement in costs and logistics compared to Imaging Technologies (NMR or PET).

Additionally, based on its capability to identify different biological substances, the spectroscopy of Raman Health Technologies can provide simultaneously information of several biomarkers with just one spectroscopic reading.

When compared to other diagnostic technologies, Raman-Laser based spectroscopy is faster, less invasive and cheaper. Additionally no reagents are needed. Raman Health Technologies can change the diagnosis of complex diseases like Alzheimer.

CRB Bio II third investment
This transaction is the third investment made by CRB Bio II, one of the largest specialized Life Science Funds in Spain, after those made in Oncovision and Amadix, for a total aggregated investment in excess of €3,5M.

“This last investment underscores our commitment to invest in disruptive technologies at early stage of development in life sciences. In the case of Raman Health Technologies, this is a very cost-effective technology, with a terrific potential and multiple application areas.” says Pablo Cabello, CSO of CRB Inverbío.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!